Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

874 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Adjuvant therapy for postmenopausal ER-positive breast cancer. Why tamoxifen still has a future? The Leuven point of view.
Neven P, Paridaens R, Amant F, Wildiers H, Berteloot P, Leunen K, Smeets A, Weltens C, van den Bogaert W, van Limbergen E, Christiaens MR, Vergote I. Neven P, et al. Among authors: vergote i. Int J Gynecol Cancer. 2006;16 Suppl 2:505-10. doi: 10.1111/j.1525-1438.2006.00682.x. Int J Gynecol Cancer. 2006. PMID: 17010059 Review. No abstract available.
Controversies regarding tamoxifen and uterine carcinoma.
Neven P, Vergote I. Neven P, et al. Among authors: vergote i. Curr Opin Obstet Gynecol. 1998 Feb;10(1):9-14. doi: 10.1097/00001703-199802000-00003. Curr Opin Obstet Gynecol. 1998. PMID: 9484623 Review.
Tamoxifen and the uterus.
Vergote I, Neven P, Vanderick G, van Dam P, Van Belle Y, De Sutter Ph, De Prins F, De Muylder X, Claerhout J, Campo R, Albertyn G. Vergote I, et al. Eur J Cancer. 1998 Aug;34 Suppl 4:S1-3. doi: 10.1016/s0959-8049(98)00174-9. Eur J Cancer. 1998. PMID: 9917139 No abstract available.
874 results